Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 501–600 of 1,007
Belibasakis, G. N., Johansson, A., Wang, Y., Chen, C., Lagergård, T., Kalfas, S., & Lerner, U. H. (2005) · Cytokine · doi:10.1016/j.cyto.2004.11.008 · Cited by 91
Osteoclast Differentiation Is Impaired in the Absence of Inhibitor of κB Kinase α
Chaisson, M. L., Branstetter, D. G., Derry, J. M. J., Armstrong, A. P., Tometsko, M. E., Takeda, K., Akira, S., & Dougall, W. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406392200 · Cited by 96
Immune changes in post-menopausal osteoporosis: the Immunos study
Breuil, V., Ticchioni, M., Testa, J., Roux, C. H., Ferrari, P. P., Breittmayer, J. P., Albert-Sabonnadière, C., Durant, J., Perreti, F. D., Bernard, A., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1018-7 · Cited by 91
“Animal studies have shown the ability of lymphocytes to regulate bone homeostasis in vivo through receptor activator for nuclear factor κ B ligand (RANKL) expression [7].”
BackgroundInterleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation
Mabilleau, G., & Sabokbar, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004173 · Cited by 92
“. The emergence of the osteoimmunology field has demonstrated that activated T cells directly modulate osteoclastogenesis and bone resorption”
BackgroundBostancı, N., İlgenli, T., Emingil, G., Afacan, B., Han, B., Töz, H., Berdeli, A., Atilla, G., McKay, I. J., Hughes, F. J., et al. (2006) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00946.x · Cited by 102
The roles of immune cells in bone healing; what we know, do not know and future perspectives
El-Jawhari, J. J., Jones, E., & Giannoudis, P. V. (2016) · Injury · doi:10.1016/j.injury.2016.10.008 · Cited by 86
Low, E., Zoellner, H. F., Kharbanda, O. P., & Darendeliler, M. A. (2005) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2004.03.038 · Cited by 99
Contemporary concepts of inflammation, damage and repair in rheumatic diseases
Luyten, F. P., Lories, R. J. U., Verschueren, P., de Vlam, K., & Westhovens, R. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.009 · Cited by 93
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin‐1 blockade
Redlich, K., Schett, G. A., Steiner, G. E., Hayer, S., Wagner, E. F., & Smolen, J. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11358 · Cited by 94
Molecular control of bone remodeling and osteoporosis
Kong, Y., & Penninger, J. M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00178-9 · Cited by 100
Self-citationRole of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss
Ofotokun, I., Titanji, K., Vikulina, T., Roser‐Page, S., Yamaguchi, M., Zayzafoon, M., Williams, I. R., & Weitzmann, M. N. (2015) · Nature Communications · doi:10.1038/ncomms9282 · Cited by 88
Li, P., Yang, X., Yang, Y., He, H., Chou, C., Chen, F., Pan, H., Liu, L., Cai, L., Ma, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.025 · Cited by 91
Bar‐Yehuda, S., Silverman, M. H., Kerns, W., Ochaion, A., Cohen, S., & Fishman, P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1601 · Cited by 86
IL-33 Exacerbates Periodontal Disease through Induction of RANKL
Malcolm, J., Awang, R. A., Oliver-Bell, J., Butcher, J. P., Campbell, L., Planell, A. A., Lappin, D. F., Fukada, S. Y., Nile, C. J., Liew, F. Y., et al. (2015) · Journal of Dental Research · doi:10.1177/0022034515577815 · Cited by 87
“OPG, the soluble decoy receptor for RANKL, is an effective inhibitor of RANK-RANKL ligation (Kong et al. 1999).”
BackgroundIntegrins, growth factors, and the osteoclast cytoskeleton
Zou, W., & Teitelbaum, S. L. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05245.x · Cited by 84
RANKL in human periapical granuloma: possible involvement in periapical bone destruction
Vernal, R., Dezerega, A., Dutzan, N., Chaparro, A. P., León, R., Chandía, S., Silva, A., & Gamonal, J. A. (2006) · Oral Diseases · doi:10.1111/j.1601-0825.2005.01191.x · Cited by 88
Ren, W., Yang, S.-Y., Fang, H.-W., Hsu, S., & Wooley, P. H. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00384-3 · Cited by 84
Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells
Di Rosa, F., & Gebhardt, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00051 · Cited by 84
Pacifici, R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12969 · Cited by 82
Megakaryocyte-mediated inhibition of osteoclast development
Kacena, M. A., Nelson, T., Clough, M. E., Lee, S., Lorenzo, J. A., Gundberg, C. M., & Horowitz, M. C. (2006) · Bone · doi:10.1016/j.bone.2006.05.004 · Cited by 92
Inducible Nitric Oxide Synthase Mediates Bone Loss in Ovariectomized Mice
Cuzzocrea, S., Mazzon, E., Dugo, L., Genovese, T., Paola, R. D., Ruggeri, Z., Vegeto, E., Caputi, A. P., van de Loo, F. A. J., Puzzolo, D., et al. (2003) · Endocrinology · doi:10.1210/en.2002-220597 · Cited by 92
Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing.
Flick, L. M., Weaver, J. M., Ulrich‐Vinther, M., Abuzzahab, F., Zhang, X., Dougall, W. C., Anderson, D., O'Keefe, R. J., & Schwarz, E. M. (2003) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(03)00011-1 · Cited by 82
RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
Tanaka, S., Tanaka, Y., Ishiguro, N., Yamanaka, H., & Takeuchi, T. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1369491 · Cited by 83
Lorenz, W., Buhrmann, C., Mobasheri, A., Lueders, C., & Shakibaei, M. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4291 · Cited by 94
Moon, S., Hong, Y.-S., Ju, J. H., Kwok, S., Park, S., & Min, J.-K. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.130356 · Cited by 84
MIP-1γ Promotes Receptor Activator of NF-κB Ligand-Induced Osteoclast Formation and Survival
Okamatsu, Y., Kim, D., Battaglino, R., Sasaki, H., Späte, U., & Stashenko, P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2084 · Cited by 81
Protective role of n-3 lipids and soy protein in osteoporosis
Fernandes, G., Lawrence, R. A., & Sun, D. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00060-7 · Cited by 94
Vernal, R., Chaparro, A., Graumann, R., Puente, J., Valenzuela, M. A., & Gamonal, J. (2004) · Journal of Periodontology · doi:10.1902/jop.2004.75.12.1586 · Cited by 81
Gasper-Smith, N., Petty, C. C., Schrum, L. W., Marriott, I., & Bost, K. L. (2002) · Infection and Immunity · doi:10.1128/iai.70.8.4075-4082.2002 · Cited by 86
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.
Gravallese, E. M., Galson, D. L., Goldring, S. R., & Auron, P. E. (2001) · Arthritis Research · doi:10.1186/ar134 · Cited by 87
The Role of Osteoclast-Associated Receptor in Osteoimmunology
Nemeth, K., Schoppet, M., Al‐Fakhri, N., Helas, S., Jessberger, R., Hofbauer, L. C., & Goettsch, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002483 · Cited by 85
“For instance, in a T cell-dependent murine arthritis model, inhibition of RANKL by OPG prevents both bone and cartilage destruction, but does not affect the inflammatory process (16).”
BackgroundT‐lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow
Di Rosa, F. (2009) · Immunology & Cell Biology · doi:10.1038/icb.2008.84 · Cited by 80
Stein, N. C., Kreutzmann, C., Zimmermann, S.-P., Niebergall, U., Hellmeyer, L., Goettsch, C., Schoppet, M., & Hofbauer, L. C. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080203 · Cited by 80
Prominent Bone Loss Mediated by RANKL and IL-17 Produced by CD4+ T Cells in TallyHo/JngJ Mice
Won, H. Y., Lee, J.-A., Park, Z. S., Song, J. S., Kim, H. Y., Jang, S.-M., Yoo, S.-E., Rhee, Y., Hwang, E. S., & Bae, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018168 · Cited by 91
“. RANKL is expressed not only in osteoblasts but also in activated CD4+ T cells”
BackgroundStolina, M., Schett, G. A., Dwyer, D., Vonderfecht, S. L., Middleton, S. C., Duryea, D., Pacheco, E., Van, G. Y., Bolon, B. N., Feige, U., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2879 · Cited by 86
Self-citationSchopf, L. R., Savinainen, A., Anderson, K., Kujawa, J., DuPont, M. M., Silva, M. J., Siebert, E. P., Chandra, S., Morgan, J. G., Gangurde, P., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22081 · Cited by 79
VanderBorght, A., Geusens, P., Raus, J., & Stinissen, P. (2001) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2001.27736 · Cited by 80
Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
Shanahan, J. C., & Clair, E. W. S. (2002) · Clinical Immunology · doi:10.1006/clim.2002.5191 · Cited by 86
Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects
Smolen, J. S., Redlich, K., Zwerina, J., Aletaha, D., Steiner, G. E., & Schett, G. A. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:239 · Cited by 81
T Cells Support Osteoclastogenesis in an In Vitro Model Derived From Human Periodontitis Patients
Brunetti, G., Colucci, S. C., Pignataro, P., Coricciati, M., Mori, G., Cirulli, N., Zallone, A. Z., Grassi, F. R., & Grano, M. (2005) · Journal of Periodontology · doi:10.1902/jop.2005.76.10.1675 · Cited by 80
Yang, C., Wang, J., Hsieh, S.-L., Wang, S. M., Hsu, T.-L., & Lin, W. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401403 · Cited by 88
Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Chiu, Y. G., & Ritchlin, C. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1263614 · Cited by 87
Campagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10369 · Cited by 78
Self-citationAnti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.
Schwarz, E. M., Looney, R. J., & O’Keefe, R. J. (2000) · Arthritis Research · doi:10.1186/ar81 · Cited by 89
Yang, S.-Y., Wu, B., Mayton, L., Mukherjee, P., Robbins, P. D., Evans, C. H., & Wooley, P. H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302192 · Cited by 79
Somayaji, S. N., Ritchie, S., Sahraei, M., Marriott, I., & Hudson, M. C. (2008) · Infection and Immunity · doi:10.1128/iai.00228-08 · Cited by 83
“RANK-L is one such key molecule that stimulates differentiation in osteoclasts and is an inducing agent involved in bone destruction (24, 25, 46, 49, 57).”
BackgroundTeng, Y.-T. A., Mahamed, D., & Singh, B. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3453-3461.2005 · Cited by 77
Non-classical monocytes as mediators of tissue destruction in arthritis
Puchner, A., Saferding, V., Bonelli, M. M., Mikami, Y., Hofmann, M., Brunner, J. S., Caldera, M., Gonçalves‐Alves, E., Binder, N. B., Fischer, A., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213250 · Cited by 87
Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis
Yang, M., & Zhu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052688 · Cited by 97
“Fixed-activated T cells were reported to act directly on osteoclast precursors shortly after RANKL cloning and to induce osteoclastogenesis by RANKL acting on T cells in vitro [53].”
BackgroundLee, S.-J., Nam, K. I., Jin, H., Cho, Y., Lee, S.-E., Kim, T., Lee, S., Kee, S., Lee, K., Kim, N., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3483 · Cited by 88
Inflammation-Induced Bone Loss: Can it Be Prevented?
Romas, E., & Gillespie, M. T. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.07.004 · Cited by 87
Vernal, R., Dutzan, N., Hernández, M., Chandía, S., Puente, J., León, R., García, L., del Valle, I., Silva, A., & Gamonal, J. A. (2006) · Journal of Periodontology · doi:10.1902/jop.2006.050376 · Cited by 86
Dufresne, S. S., Dumont, N. A., Boulanger-Piette, A., Fajardo, V. A., Gamu, D., Kake-Guena, S.-A., David, R. O., Bouchard, P., Lavergne, É., Penninger, J. M., et al. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00285.2015 · Cited by 76
Self-citationHIV infection and bone disease
Compston, J. E. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12520 · Cited by 89
Experience in the Adaptive Immunity Impacts Bone Homeostasis, Remodeling, and Healing
Bucher, C. H., Schlundt, C., Wulsten, D., Sass, F. A., Wendler, S., Ellinghaus, A., Thiele, T., Seemann, R., Willie, B. M., Volk, H.-D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00797 · Cited by 76
“That the more proinflammatory state of the experienced immune system with high numbers of TNFα producing effector memory T cells could be responsible for reduced bone formation or even bone loss is also mirrored in previous studies where activated T cells have been correlated to bone loss in conditions of inflammation…”
ResultShimizu, S., Asou, Y., Itoh, S., Chung, U., Kawaguchi, H., Shinomiya, K., & Muneta, T. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22941 · Cited by 79
Stolina, M., Bolon, B. N., Middleton, S. C., Dwyer, D., Brown, H., Duryea, D., Zhu, L., Rohner, A., Pretorius, J. K., Kostenuik, P. J., et al. (2008) · Journal of Clinical Immunology · doi:10.1007/s10875-008-9238-8 · Cited by 81
Self-citationRelationship between serum RANKL and RANKL in bone
Findlay, D. M., & Atkins, G. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1740-9 · Cited by 85
Marriott, I., Gray, D. L., Rati, D. M., Fowler, V. G., Stryjewski, M. E., Levin, L. S., Hudson, M. C., & Bost, K. L. (2005) · Bone · doi:10.1016/j.bone.2005.05.011 · Cited by 79
“A number of studies have clearly shown that activated T-lymphocytes [25–29] and macrophages [30–33] can be responsible for bone loss and can mediate bone resorption.”
BackgroundRANKL/RANK: from bone loss to the prevention of breast cancer
Sigl, V., Jones, L. P., & Penninger, J. M. (2016) · Open Biology · doi:10.1098/rsob.160230 · Cited by 76
Self-citationUrushibara, M., Takayanagi, H., Koga, T., Kim, S., Isobe, M., Morishita, Y., Nakagawa, T., Loeffler, M. L., Kodama, T., Kurosawa, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20206 · Cited by 78
Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis
A. J. Feuerherm, M. B. (2001) · Scandinavian Journal of Rheumatology · doi:10.1080/030097401316909585 · Cited by 76
Immunostimulatory DNA Sequences Influence the Course of Adjuvant Arthritis
Ronaghy, A., Prakken, B. J., Takabayashi, K., Firestein, G. S., Boyle, D., Zvailfler, N. J., Roord, S. T. A., Albani, S., Carson, D. A., & Raz, E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.51 · Cited by 76
Physiological Functions of Osteoblast Lineage and T Cell–Derived RANKL in Bone Homeostasis
Fumoto, T., Takeshita, S., Ito, M., & Ikeda, K. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2096 · Cited by 75
Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02534.x · Cited by 74
Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells
Kanamaru, F., Iwai, H., Ikeda, T., Nakajima, A., Ishikawa, I., & Azuma, M. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.05.010 · Cited by 90
Li, B., Wang, P., Jiao, J., Wei, H., Xu, W., & Zhou, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.824117 · Cited by 98
Kotake, S., Yago, T., Kawamoto, M., & Nanke, Y. (2011) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-011-0321-5 · Cited by 78
Osteoclasts—Key Players in Skeletal Health and Disease
Novack, D. V., & Mbalaviele, G. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0011-2015 · Cited by 86
Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2166 · Cited by 83
Wang, J., Yu, L., Jiang, C. Q., Fu, X., Liu, X., Wang, M., Ou, C., Cui, X., Zhou, C., & Wang, J. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.07.022 · Cited by 72
“It is well known that RANKL is mainly expressed by lymphocytes, especially CD4+ T cells in bone marrow in response to immunostimulation (Kong et al., 1999; Loser et al., 2006).”
Role of TGF-β in breast cancer bone metastases
Chiechi, A., Waning, D. L., Stayrook, K. R., Buijs, J. T., Guise, T. A., & Mohammad, K. S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.410a4003 · Cited by 77
“RANKL/RANK knockout mice develop severe osteopetrosis due to total lack of osteoclast [83,84].”
BackgroundDemer, L. L., & Tintut, Y. (2011) · Circulation Research · doi:10.1161/circresaha.110.234245 · Cited by 89
Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis
Fessler, J., Husic, R., Theiler‐Schwetz, V., Lerchbaum, E., Aberer, F., Fasching, P., Ficjan, A., Obermayer-Pietsch, B. M., Duftner, C., Graninger, W. B., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00095 · Cited by 84
“in 1999 by illustrating that T-cell-produced receptor activator of nuclear factor kappa-B ligand (RANKL) triggered osteoclastogenesis directly in a mouse model of adjuvant-induced arthritis (5).”
BackgroundSignaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System
Tanaka, S. (2007) · American Journal of Nephrology · doi:10.1159/000106484 · Cited by 84
“Bone marrow biopsies from patients with myeloma exhibit an increase of RANKL and a reduction of OPG expression upon immunohistochemical analysis [ , , ,”
BackgroundTherapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus
Lane, N. E. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0298 · Cited by 72
Dendritic cell responses to surface properties of clinical titanium surfaces
Kou, P. M., Schwartz, Z., Boyan, B. D., & Babensee, J. E. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.10.020 · Cited by 73
Paniagua, R. T., Chang, A., Mariano, M. M., Stein, E. A., Wang, Q., Lindstrom, T. M., Sharpe, O., Roscow, C., Ho, P. P., Lee, D. M., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2940 · Cited by 73
Bone and joint destruction in rheumatoid arthritis: what is really happening?
Goldring, S. R. (2002) · PubMed · Cited by 97
FRANCHIMONT, N., REENAERS, C., LAMBERT, C., BELAICHE, J., BOURS, V, MALAISE, M., DELVENNE, P., & LOUIS, E. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02643.x · Cited by 73
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.
Rehman, Q., & Lane, N. E. (2001) · Arthritis Research · doi:10.1186/ar305 · Cited by 76
Seshasayee, D., Wang, H., Lee, W. P., Gribling, P., Ross, J., Van Bruggen, N., Carano, R., & Grewal, I. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403968200 · Cited by 73
Effector lymphocytes in autoimmunity
Santamaría, P. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(01)00276-x · Cited by 81
Hofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72
Basic and clinical aspects of osteoporosis in inflammatory bowel disease
Rodríguez-Bores, L., Barahona-Garrido, J., & Yamamoto-Furusho, J. K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i46.6156 · Cited by 72
Identification of RANKL in Osteolytic Lesions of the Facial Skeleton
Tay, J., Bay, B., Yeo, J. F., Harris, M., Meghji, S., & Dheen, S. T. (2004) · Journal of Dental Research · doi:10.1177/154405910408300415 · Cited by 77
“The primary secreted form is limited to activated T-cells (Kong et al., 1999) and a squamous cell carcinoma cell line (Nagai et al., 2000).”
BackgroundJensen, T. S., Klarlund, M., Hansen, M., Jensen, K. E., Pødenphant, J., Hansen, T. M., Skjødt, H., & Hyldstrup, L. H. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013888 · Cited by 72
Görtz, B., Hayer, S., Tuerk, B., Zwerina, J., Smolen, J. S., & Schett, G. A. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1797 · Cited by 70
Nakajima, S., Iijima, H., Egawa, S., Shinzaki, S., Kondo, J., Inoue, T., Hayashi, Y., Jin, Y., Mukai, A., Akasaka, T., et al. (2011) · Nutrition · doi:10.1016/j.nut.2010.10.021 · Cited by 72
The dynamic interplay between osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.004 · Cited by 78
Schett, G. A., Stolina, M., Dwyer, D., Zack, D. J., Uderhardt, S., Krönke, G., Kostenuik, P. J., & Feige, U. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24767 · Cited by 79
Self-citationMebarek, S., Abousalham, A., Magne, D., Do, L.-D., Bandorowicz‐Pikuła, J., Pikuła, S., & Buchet, R. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035036 · Cited by 80
The emerging roles of B cells as partners and targets in periodontitis
Zouali, M. (2016) · Autoimmunity · doi:10.1080/08916934.2016.1261841 · Cited by 76
Osteomicrobiology: A New Cross-Disciplinary Research Field
Ohlsson, C., & Sjögren, K. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0336-6 · Cited by 79
Lubberts, E., Oppers‐Walgreen, B., Pettit, A. R., Van Den Bersselaar, L., Joosten, L. A. B., Goldring, S. R., Gravallese, E. M., & Van Den Berg, W. B. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10607 · Cited by 71
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
RANKL as a target for the treatment of osteoporosis
Matsumoto, T., & Endo, I. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01153-7 · Cited by 76
“However, RANKL inhibition via OPG suppresses bone resorption without measurable effects on inflammation [41], suggesting that RANKL might play a redundant role in the postnatal immune system.”
BackgroundTrebec‐Reynolds, D. P., Chandra, D., Gramoun, A., Li, K., Heersche, J. N. M., & Manolson, M. F. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21171 · Cited by 77
“The increase in OC size likely results from the increased level of sRANKL and other inflammatory cytokines, which in turn results from the increased presence of inflammatory cells [Kong et al., 1999].”
BackgroundSoluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice
Lloyd, S. A. J., Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Lau, A. G., Morony, S., Stolina, M., Asuncion, F., & Bateman, T. A. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9133-6 · Cited by 77
Self-citationvon Tirpitz, C., Epp, S., Klaus, J., Mason, R., Hawa, G., Brinskelle-Schmal, N., Hofbauer, L. C., Adler, G., Kratzer, W., & Reinshagen, M. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200311000-00003 · Cited by 69
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.